EB病毒特异性细胞毒T淋巴细胞治疗复发难治性NK/T细胞淋巴瘤(鼻型)1例报告并文献复习

EPSTEIN-BARR VIRUS-SPECIFIC CYTOTOXIC T CELLS IN TREATMENT OF RECURRENT REFRACTORY NATURAL KILLER/T-CELL LYMPHOMA (NASAL TYPE): A CASE REPORT AND LITERATURE REVIEW

目的探讨EB病毒特异性细胞毒T淋巴细胞(EBV-CTL)治疗复发难治性NK/T细胞淋巴瘤(鼻型)的可行性。方法报告1例女性结外NK/T细胞淋巴瘤(鼻型)病人,病人给予培门冬酶+GDP方案化疗以及2 Gy(12次)局部放疗,病情进展,免疫组化检测EBER阳性,再次给予3疗程EBV-CTL治疗。结果病人采用EBV-CTL治疗后4个月达到完全缓解,而且细胞治疗过程中无明显不良反应,病人耐受性好。结论 EBV-CTL可以作为治疗复发难治性NK/T细胞淋巴瘤的一个选择。

Objective To investigate the feasibility of Epstein-Barr virus-specific cytotoxic T cells(EBV-CTL) in the treatment of recurrent refractory natural killer/T-cell lymphoma(nasal type). Methods This article reported a female patient with extranodal natural killer/T-cell lymphoma. The patient was given chemotherapy with pegaspargase-GDP regimen and local radiotherapy at a dose of 2 Gy for 12 times. Disease progression was observed and immunochemistry showed positive EBER. The patient was given another three courses of EBV-CTL therapy. Results The patient achieved complete remission at 4 months after EBV-CTL therapy. No obvious adverse reactions were observed during the treatment, and the patient had good tolerance. Conclusion EBV-CTL therapy can be used as a choice for the treatment of recurrent refractory natural killer/T-cell lymphoma.